BBC Russian

12 pages, 881 KiB

Open AccessArticle

Health Literacy and Clinical Trial Participation in French Cancer Patients: A National Survey

by Youssoufa M. Ousseine, Anne-Déborah Bouhnik and Julien Mancini

Curr. Oncol. 2022, 29(5), 3118-3129; https://doi.org/10.3390/curroncol29050253 - 28 Apr 2022

Cited by 13 | Viewed by 2523

Few studies have explored the relationship between health literacy (HL) and trial participation. In this context, we aimed to study this relationship in French cancer patients. We used data from the French national VIe après le CANcer (VICAN) survey. Two questionnaire items focused on previous invitations to participate in clinical trials and subsequent enrollment. The Single Item Literacy Screener was used to measure functional HL. In total, 1954 cancer patients responded to both VICAN surveys (two and five years after diagnosis). Mean age was 54.1 ± 12.7 years at diagnosis, and 37.6% were classified as having limited HL. One in ten (10.3%) respondents reported having been previously invited to participate in a clinical trial. Of these, 75.5% had enrolled. Limited HL was associated with fewer trial invitations but not with enrollment once invited. Multivariate analysis confirmed the negative effect of limited HL on clinical trial invitation (adjOR = 0.55 (0.39 to 0.77), p < 0.001) after adjustment for multiple characteristics. Patients with limited HL received fewer invitations to participate in trials but were likely to enroll when asked. Addressing HL is necessary to create a more inclusive health system and to reduce inequalities not only in access to innovative cancer care, but to health inequalities in general. Full article

► Show Figures

Figure 1

17 pages, 6659 KiB

Open AccessArticle

Patterns of Sequelae in Women with a History of Localized Breast Cancer: Results from the French VICAN Survey

by Lidia Delrieu, Liacine Bouaoun, Douae El Fatouhi, Elise Dumas, Anne-Deborah Bouhnik, Hugo Noelle, Emmanuelle Jacquet, Anne-Sophie Hamy, Florence Coussy, Fabien Reyal, Pierre-Etienne Heudel, Marc-Karim Bendiane, Baptiste Fournier, Mauricette Michallet, Béatrice Fervers, Guy Fagherazzi and Olivia Pérol

Cancers 2021, 13(5), 1161; https://doi.org/10.3390/cancers13051161 - 8 Mar 2021

Cited by 5 | Viewed by 3106

Abstract

Breast cancer (BC) remains complex for women both physically and psychologically. The objectives of this study were to (1) assess the evolution of the main sequelae and treatment two and five years after diagnosis in women with early-stage breast cancer, (2) explore patterns of sequelae associated with given sociodemographic, clinical, and lifestyle factors. The current analysis was based on 654 localized BC patients enrolled in the French nationwide longitudinal survey “vie après cancer” VICAN (January–June 2010). Information about study participants was collected at enrollment, two and five years after diagnosis. Changes over time of the main sequelae were analyzed and latent class analysis was performed to identify patterns of sequelae related to BC five years after diagnosis. The mean age (±SD) of study participants at inclusion was 49.7 (±10.5) years old. Six main classes of sequelae were identified two years and five years post-diagnosis (functional, pain, esthetic, fatigue, psychological, and gynecological). A significant decrease was observed for fatigue (p = 0.03) and an increase in cognitive sequelae was reported (p = 0.03). Two latent classes were identified—functional and esthetic patterns. Substantial sequelae remain up to five years after BC diagnosis. Changes in patient care pathways are needed to identify BC patients at a high risk. Full article

► Show Figures

Figure 1

21 pages, 644 KiB

Open AccessArticle

Deterioration of Sexual Health in Cancer Survivors Five Years after Diagnosis: Data from the French National Prospective VICAN Survey

by Lorène Seguin, Rajae Touzani, Anne-Déborah Bouhnik, Ali Ben Charif, Patricia Marino, Marc-Karim Bendiane, Anthony Gonçalves, Gwenaelle Gravis and Julien Mancini

Cancers 2020, 12(11), 3453; https://doi.org/10.3390/cancers12113453 - 20 Nov 2020

Cited by 15 | Viewed by 2243

Abstract

Little is known about cancer survivors’ sexual health (SH)—particularly, from well after diagnosis and in cancers unrelated to sexuality. This study aimed to assess SH deterioration five years after diagnosis. We analyzed data from the French national VIe après le CANcer (VICAN) survey. Six items from the Relationship and Sexuality Scale were used to assess SH. Respondents were grouped according to an ascending hierarchical classification in four clusters: strong, moderate, and weak deterioration or stable (WD, SD, MD, or St). Out of 2195 eligible participants, 57.3% reported substantial SH deterioration as either SD (30.8%) or MD (26.5%), while WD and St accounted for 31.2% and 11.5% of respondents, respectively. Substantial deterioration was reported in all cancer sites (from 27.7% in melanoma to 83.1% in prostate). Treatment type, cancer sequelae, and pain, as well as psychological consequences (depression and anxiety, especially for younger patients) were associated with substantial SH deterioration. The same factors were identified after restricting the analysis to survivors of cancers unrelated to sexuality. Five years after diagnosis, the majority of cancer survivors reported SH deterioration. Interventions should be developed to improve SH regardless of cancer site. Particular attention should be paid to depression and anxiety, especially in younger survivors. Full article

► Show Figures

Figure 1

Search Results (3)

Further Information

Guidelines

MDPI Initiatives

Follow MDPI

Saved Queries

Search Filter Reset All

Years

Feature Papers

Subjects

Journals

Article Types

Countries / Regions

Search Results (3)

Further Information

Guidelines

MDPI Initiatives

Follow MDPI